ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Zacks Investment Research on MSN
IBRX stock jumps on progress in NK cell therapy production
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to finish at $8.39 apiece, as investors took heart from the company’s optimism ...
A newly discovered genetic switch may allow scientists to dramatically amplify the cancer-killing power of natural immune cells by harnessing the body’s own signaling molecules. Credit: Shutterstock ...
Natural killer cells, also referred to as NK cells, play several major roles in the body's defense against cancers like renal cell carcinoma. Natural killer cells, also referred to as NK cells, play ...
Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...
Some types of CD8+ T cells (killer T cells) may play a role in the development of multiple sclerosis (MS). This is according to data from a new study published in Nature Immunology. Specifically, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results